Sharon E Frey1, Jack T Stapleton2, Zuhair K Ballas2, Wendy L Rasmussen2, Thomas M Kaufman2, Tammy P Blevins1, Travis L Jensen3, D Huw Davies4, Magdalena Tary-Lehmann5, Paul Chaplin6, Heather Hill3, Johannes B Goll3. 1. Department of Internal Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA. 2. Department of Internal Medicine, University of Iowa and Iowa City VA Medical Center, Iowa City, Iowa, USA. 3. Emmes, Rockville, Maryland, USA. 4. Vaccine Research & Development Center, Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, California, USA. 5. Cellular Technology Limited, Shaker Heights, Ohio, USA. 6. Bavarian Nordic, Martinsried, Germany.
Abstract
BACKGROUND: There are limited data regarding immunological correlates of protection for the modified vaccinia Ankara (MVA) smallpox vaccine. METHODS: A total of 523 vaccinia-naive subjects were randomized to receive 2 vaccine doses, as lyophilized MVA given subcutaneously, liquid MVA given subcutaneously (liquid-SC group), or liquid MVA given intradermally (liquid-ID group) 28 days apart. For a subset of subjects, antibody-dependent cellular cytotoxicity (ADCC), interferon-γ release enzyme-linked immunospot (ELISPOT), and protein microarray antibody-binding assays were conducted. Protein microarray responses were assessed for correlations with plaque reduction neutralization titer (PRNT), enzyme-linked immunosorbent assay, ADCC, and ELISPOT results. RESULTS: MVA elicited significant microarray antibody responses to 15 of 224 antigens, mostly virion membrane proteins, at day 28 or 42, particularly WR113/D8L and WR101H3L. In the liquid-SC group, responses to 9 antigens, including WR113/D8L and WR101/H3L, correlated with PRNT results. Three were correlated in the liquid-ID group. No significant correlations were observed with ELISPOT responses. In the liquid-ID group, WR052/F13L, a membrane glycoprotein, correlated with ADCC responses. CONCLUSIONS: MVA elicited antibodies to 15 vaccinia strain antigens representing virion membrane. Antibody responses to 2 proteins strongly increased and significantly correlated with increases in PRNT. Responses to these proteins are potential correlates of protection and may serve as immunogens for future vaccine development. CLINICAL TRIALS REGISTRATION: NCT00914732.
BACKGROUND: There are limited data regarding immunological correlates of protection for the modified vaccinia Ankara (MVA) smallpox vaccine. METHODS: A total of 523 vaccinia-naive subjects were randomized to receive 2 vaccine doses, as lyophilized MVA given subcutaneously, liquid MVA given subcutaneously (liquid-SC group), or liquid MVA given intradermally (liquid-ID group) 28 days apart. For a subset of subjects, antibody-dependent cellular cytotoxicity (ADCC), interferon-γ release enzyme-linked immunospot (ELISPOT), and protein microarray antibody-binding assays were conducted. Protein microarray responses were assessed for correlations with plaque reduction neutralization titer (PRNT), enzyme-linked immunosorbent assay, ADCC, and ELISPOT results. RESULTS: MVA elicited significant microarray antibody responses to 15 of 224 antigens, mostly virion membrane proteins, at day 28 or 42, particularly WR113/D8L and WR101H3L. In the liquid-SC group, responses to 9 antigens, including WR113/D8L and WR101/H3L, correlated with PRNT results. Three were correlated in the liquid-ID group. No significant correlations were observed with ELISPOT responses. In the liquid-ID group, WR052/F13L, a membrane glycoprotein, correlated with ADCC responses. CONCLUSIONS: MVA elicited antibodies to 15 vaccinia strain antigens representing virion membrane. Antibody responses to 2 proteins strongly increased and significantly correlated with increases in PRNT. Responses to these proteins are potential correlates of protection and may serve as immunogens for future vaccine development. CLINICAL TRIALS REGISTRATION: NCT00914732.
Authors: D Huw Davies; Douglas M Molina; Jens Wrammert; Joe Miller; Siddiqua Hirst; Yunxiang Mu; Jozelyn Pablo; Berkay Unal; Rie Nakajima-Sasaki; Xiaowu Liang; Shane Crotty; Kevin L Karem; Inger K Damon; Rafi Ahmed; Luis Villarreal; Philip L Felgner Journal: Proteomics Date: 2007-05 Impact factor: 3.984
Authors: Marissa B Wilck; Michael S Seaman; Lindsey R Baden; Stephen R Walsh; Lauren E Grandpre; Colleen Devoy; Ayush Giri; Jane A Kleinjan; Lizanne C Noble; Kristen E Stevenson; Haesook T Kim; Raphael Dolin Journal: J Infect Dis Date: 2010-05-01 Impact factor: 5.226
Authors: Jordan S Orange; Scott R Brodeur; Ashish Jain; Francisco A Bonilla; Lynda C Schneider; Roberto Kretschmer; Samuel Nurko; Wendy L Rasmussen; Julia R Köhler; Stephen E Gellis; Betsy M Ferguson; Jack L Strominger; Jonathan Zonana; Narayanaswamy Ramesh; Zuhair K Ballas; Raif S Geha Journal: J Clin Invest Date: 2002-06 Impact factor: 14.808
Authors: V Raúl Gómez-Román; L Jean Patterson; David Venzon; David Liewehr; Kris Aldrich; Ruth Florese; Marjorie Robert-Guroff Journal: J Immunol Date: 2005-02-15 Impact factor: 5.422
Authors: Stephen R Walsh; Marissa B Wilck; David J Dominguez; Elise Zablowsky; Shringkhala Bajimaya; Lisa S Gagne; Kelly A Verrill; Jane A Kleinjan; Alka Patel; Ying Zhang; Heather Hill; Aruna Acharyya; David C Fisher; Joseph H Antin; Michael S Seaman; Raphael Dolin; Lindsey R Baden Journal: J Infect Dis Date: 2013-03-12 Impact factor: 5.226
Authors: Tobias R Schlingmann; Carey L Shive; Oleg S Targoni; Magdalena Tary-Lehmann; Paul V Lehmann Journal: Cell Immunol Date: 2009-05-08 Impact factor: 4.868